Rethinking Endpoints: How Lesion Location Drives Clinically Meaningful Measures of Impact in Dry AMD
Time: 11:30 am
day: Day1
Details:
- Understanding why lesion location, not just size or growth, is emerging as a more meaningful predictor of vision-threatening progression in dry AMD
- Discuss how spatial distribution of atrophy may influence endpoint sensitivity, patient stratification, and the interpretation of therapeutic benefit.
- Sharing insights from clinical data on spatial lesion impact to refine trial endpoints and improve outcome relevance
